Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Executive Officer

700,000 1.1700%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+0.47%+2.27%+50.78%+69.72% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+1.12%+2.52%-15.55%-13.53% 23.38B
-1.07%-2.03%-0.50%+372.97% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%-2.30%+27.27%-33.01% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-1.99%+1.93%+51.71%+184.32% 14.2B
Average -1.70%-0.56%+40.64%+164.77% 26.35B
Weighted average by Cap. +0.36%-0.20%+37.62%+129.58%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock